Mellitus Reports Publication of Investigator-Initiated Study Supporting Glycated CD59 as a Novel Alternative for Gestational Diabetes Screening

Mellitus Reports Publication of Investigator-Initiated Study Supporting Glycated CD59 as a Novel Alternative for Gestational Diabetes Screening

-A single blood test to measure GCD59 at week 24-28 of gestation identified women with gestational diabetes with high sensitivity and specificity-

-GCD59 technology to advance diabetes detection and monitoring under exclusive license by Mellitus from Harvard University-

BOSTON, Mass., April 27, 2017 – Mellitus, LLC today reported the publication of results from a prospective, investigator-initiated study conducted at Brigham and Women’s Hospital (BWH) demonstrating the potential clinical utility of glycated CD59 (GCD59) as a novel biomarker for the screening and diagnosis of gestational diabetes mellitus (GDM). The data from this study showed that a single blood test that measures plasma GCD59 at week 24-28 of gestation identified women with GDM with high sensitivity and specificity. The study was completed by a team of investigators at BWH led by Jose A. Halperin, M.D., in collaboration with researchers from Harvard T.H. Chan School of Public Health. Dr. Halperin, scientific Co-founder of Mellitus, is a physician and researcher at BWH and Associate Professor of Medicine at Harvard Medical School (HMS). The paper titled, “Plasma Glycated CD59, a Novel Biomarker for Detection of Pregnancy-Induced Glucose Intolerance,” was published online ahead of print in the Novel Communications in Diabetes section of Diabetes Care, an American Diabetes Association journal.

Mellitus Diabetes Care Publication Release FINAL 04.27.17[1]